| __timestamp | Bristol-Myers Squibb Company | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 14400000 |
| Thursday, January 1, 2015 | 3909000000 | 33800000 |
| Friday, January 1, 2016 | 4946000000 | 35900000 |
| Sunday, January 1, 2017 | 6066000000 | 1254000 |
| Monday, January 1, 2018 | 6547000000 | 4889000 |
| Tuesday, January 1, 2019 | 8078000000 | 7400000 |
| Wednesday, January 1, 2020 | 11773000000 | 10100000 |
| Friday, January 1, 2021 | 9940000000 | 14300000 |
| Saturday, January 1, 2022 | 10137000000 | 23200000 |
| Sunday, January 1, 2023 | 10693000000 | 39700000 |
| Monday, January 1, 2024 | 11949000000 | 34000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue trends for Bristol-Myers Squibb Company and Neurocrine Biosciences, Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb's cost of revenue surged by approximately 172%, peaking in 2020. This reflects their aggressive expansion and increased production capabilities. In contrast, Neurocrine Biosciences, a smaller player, saw a more modest increase of around 176%, highlighting their strategic focus on niche markets. Notably, 2023 marked a significant year for Neurocrine, with a 71% increase from the previous year, indicating potential growth in their market share. These insights underscore the dynamic nature of the pharmaceutical sector, where cost management and strategic investments are pivotal for sustained growth.
Analyzing Cost of Revenue: Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down Novartis AG and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Pfizer Inc. vs Bristol-Myers Squibb Company
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and United Therapeutics Corporation
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Neurocrine Biosciences, Inc.'s Expenses
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored